Pub Date : 2024-11-01DOI: 10.3324/haematol.2024.286256
Emmanuel Olivier, Shouping Zhang, Zi Yan, Eric E Bouhassira
{"title":"<i>Erratum</i> to: Stem cell factor and erythropoietin-independent production of cultured reticulocytes.","authors":"Emmanuel Olivier, Shouping Zhang, Zi Yan, Eric E Bouhassira","doi":"10.3324/haematol.2024.286256","DOIUrl":"10.3324/haematol.2024.286256","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"109 11","pages":"3829-3831"},"PeriodicalIF":8.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142566627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.3324/haematol.2023.284417
Corrado Girmenia, Fabio Ciceri, Paolo Corradini, Antonio Cuneo, Fortunato D'Ancona, Pellegrino Musto, Antonio Maria Risitano, Maria Teresa Voso, Adriano Venditti, Giovanni Barosi
The identification of patients at high risk of Herpes zoster (HZ) requiring a preventive strategy with antiviral prophylaxis and anti-HZ vaccine is a clinically relevant issue in patients with immunological impairment. The absence of trials comparing vaccination to pharmacological prophylaxis or defining their sequential use makes the optimal preventive strategy uncertain. This article presents the results of group discussion among a panel of experts convened ad hoc to review the literature regarding antiviral prophylaxis and vaccine efficacy and safety in populations with malignant and non-malignant hematologic diseases, and in subjects submitted to hematopoietic stem cell transplantation. The expert panel used consensus methodology and proposed solutions for preventive strategies, producing advice for the management of the most relevant unmet clinical needs. This comprehensive overview aims to support the practice of pharmacological and vaccination-based HZ prevention and inform the design and conduct of new studies in the field.
{"title":"Towards personalized prevention of Herpes zoster infection in patients with hematologic diseases or hematopoietic stem cell transplant recipients: a position paper from an <I>ad hoc</I> Italian expert panel.","authors":"Corrado Girmenia, Fabio Ciceri, Paolo Corradini, Antonio Cuneo, Fortunato D'Ancona, Pellegrino Musto, Antonio Maria Risitano, Maria Teresa Voso, Adriano Venditti, Giovanni Barosi","doi":"10.3324/haematol.2023.284417","DOIUrl":"10.3324/haematol.2023.284417","url":null,"abstract":"<p><p>The identification of patients at high risk of Herpes zoster (HZ) requiring a preventive strategy with antiviral prophylaxis and anti-HZ vaccine is a clinically relevant issue in patients with immunological impairment. The absence of trials comparing vaccination to pharmacological prophylaxis or defining their sequential use makes the optimal preventive strategy uncertain. This article presents the results of group discussion among a panel of experts convened ad hoc to review the literature regarding antiviral prophylaxis and vaccine efficacy and safety in populations with malignant and non-malignant hematologic diseases, and in subjects submitted to hematopoietic stem cell transplantation. The expert panel used consensus methodology and proposed solutions for preventive strategies, producing advice for the management of the most relevant unmet clinical needs. This comprehensive overview aims to support the practice of pharmacological and vaccination-based HZ prevention and inform the design and conduct of new studies in the field.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"3496-3504"},"PeriodicalIF":5.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138803365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.3324/haematol.2023.284552
Man Wai Tang, Erfan Nur, Charlotte F J Van Tuijn, Bart J Biemond
{"title":"Prevalence of autoimmune diseases in patients with sickle cell disease: a single center retrospective analysis.","authors":"Man Wai Tang, Erfan Nur, Charlotte F J Van Tuijn, Bart J Biemond","doi":"10.3324/haematol.2023.284552","DOIUrl":"10.3324/haematol.2023.284552","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"3735-3738"},"PeriodicalIF":8.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140305431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.3324/haematol.2024.285426
Jian Xu, Wei Du
{"title":"HES6: an emerging player in human hematopoiesis.","authors":"Jian Xu, Wei Du","doi":"10.3324/haematol.2024.285426","DOIUrl":"10.3324/haematol.2024.285426","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"3466-3468"},"PeriodicalIF":8.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532680/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140891870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.3324/haematol.2024.286215
Marco Cattaneo
{"title":"Aspirin is a life-saving drug for patients with acute myocardial infarction.","authors":"Marco Cattaneo","doi":"10.3324/haematol.2024.286215","DOIUrl":"10.3324/haematol.2024.286215","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"109 11","pages":"3459-3460"},"PeriodicalIF":8.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532675/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142566812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.3324/haematol.2024.285821
Umair Munawar, Johanna Theuersbacher, Maximilian J Steinhardt, Xiang Zhou, Seungbin Han, Silvia Nerreter, Cornelia Vogt, Shilpa Kurian, Thorsten Keller, Ann-Katrin Regensburger, Eva Teufel, Julia Mersi, Max Bittrich, Franziska Seifert, Malik S Haider, Leo Rasche, Jost Hillenkamp, Hermann Einsele, Daniel Kampik, K Martin Kortüm, Johannes M Waldschmidt
{"title":"<i>Erratum</i> to: Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma.","authors":"Umair Munawar, Johanna Theuersbacher, Maximilian J Steinhardt, Xiang Zhou, Seungbin Han, Silvia Nerreter, Cornelia Vogt, Shilpa Kurian, Thorsten Keller, Ann-Katrin Regensburger, Eva Teufel, Julia Mersi, Max Bittrich, Franziska Seifert, Malik S Haider, Leo Rasche, Jost Hillenkamp, Hermann Einsele, Daniel Kampik, K Martin Kortüm, Johannes M Waldschmidt","doi":"10.3324/haematol.2024.285821","DOIUrl":"10.3324/haematol.2024.285821","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"109 11","pages":"3828"},"PeriodicalIF":8.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142566626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.3324/haematol.2024.285253
Valentino Conter, Maria Grazia Valsecchi, Paola De Lorenzo, Virginie Gandemer, Mats Heyman, Vaskar Saha, Paulina Diaz, Chi-Kong Li, Andishe Attarbaschi, Gabriele Escherich, Jan Stary, Martin Schrappe, Rob Pieters, Gunnar Cario, Andrea Biondi
{"title":"No clear benefit of preventive cranial radiotherapy in childhood Philadelphia-positive acute lymphoblastic leukemia: a retrospective analysis of the EsPhALL2010 study.","authors":"Valentino Conter, Maria Grazia Valsecchi, Paola De Lorenzo, Virginie Gandemer, Mats Heyman, Vaskar Saha, Paulina Diaz, Chi-Kong Li, Andishe Attarbaschi, Gabriele Escherich, Jan Stary, Martin Schrappe, Rob Pieters, Gunnar Cario, Andrea Biondi","doi":"10.3324/haematol.2024.285253","DOIUrl":"10.3324/haematol.2024.285253","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"3766-3770"},"PeriodicalIF":8.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141633293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Primary vitreoretinal lymphoma (PVRL) is a rare malignant lymphoma subtype with an unfavorable prognosis due to frequent central nervous system (CNS) progression. Thus, identifying factors associated with CNS progression is essential for improving the prognosis of PVRL patients. Accordingly, we conducted a comprehensive genetic analysis using archived vitreous humor samples of 36 PVRL patients diagnosed and treated at our institution and retrospectively examined the relationship between genetic alterations and CNS progression. Whole-exome sequencing (N=2) and amplicon sequencing using a custom panel of 107 lymphomagenesis-related genes (N=34) were performed to assess mutations and copy number alterations. The median number of pathogenic genetic alterations per case was 12 (range, 0-22). Pathogenic genetic alterations of CDKN2A, MYD88, CDKN2B, PRDM1, PIM1, ETV6, CD79B, and IGLL5, as well as aberrant somatic hypermutations, were frequently detected. The frequency of ETV6 loss and PRDM1 alteration (mutation and loss) was 23% and 49%, respectively. Multivariate analysis revealed ETV6 loss (hazard ratio [HR]=3.26, 95% confidence interval [CI]: 1.08-9.85) and PRDM1 alteration (HR=2.52, 95% CI: 1.03-6.16) as candidate risk factors associated with CNS progression of PVRL. Moreover, these two genetic factors defined slow-, intermediate-, and rapid-progression groups (0, 1, and 2 factors, respectively), and the median period to CNS progression differed significantly among them (52 vs. 33 vs. 20 months, respectively). Our findings suggest that genetic factors predict the CNS progression of PVRL effectively, and the genetics-based CNS progression model might lead to stratification of treatment.
{"title":"Impact of genetic alterations on central nervous system progression of primary vitreoretinal lymphoma.","authors":"Kota Yoshifuji, Daichi Sadato, Takashi Toya, Yotaro Motomura, Chizuko Hirama, Hiroshi Takase, Kouhei Yamamoto, Yuka Harada, Takehiko Mori, Toshikage Nagao","doi":"10.3324/haematol.2023.284953","DOIUrl":"10.3324/haematol.2023.284953","url":null,"abstract":"<p><p>Primary vitreoretinal lymphoma (PVRL) is a rare malignant lymphoma subtype with an unfavorable prognosis due to frequent central nervous system (CNS) progression. Thus, identifying factors associated with CNS progression is essential for improving the prognosis of PVRL patients. Accordingly, we conducted a comprehensive genetic analysis using archived vitreous humor samples of 36 PVRL patients diagnosed and treated at our institution and retrospectively examined the relationship between genetic alterations and CNS progression. Whole-exome sequencing (N=2) and amplicon sequencing using a custom panel of 107 lymphomagenesis-related genes (N=34) were performed to assess mutations and copy number alterations. The median number of pathogenic genetic alterations per case was 12 (range, 0-22). Pathogenic genetic alterations of CDKN2A, MYD88, CDKN2B, PRDM1, PIM1, ETV6, CD79B, and IGLL5, as well as aberrant somatic hypermutations, were frequently detected. The frequency of ETV6 loss and PRDM1 alteration (mutation and loss) was 23% and 49%, respectively. Multivariate analysis revealed ETV6 loss (hazard ratio [HR]=3.26, 95% confidence interval [CI]: 1.08-9.85) and PRDM1 alteration (HR=2.52, 95% CI: 1.03-6.16) as candidate risk factors associated with CNS progression of PVRL. Moreover, these two genetic factors defined slow-, intermediate-, and rapid-progression groups (0, 1, and 2 factors, respectively), and the median period to CNS progression differed significantly among them (52 vs. 33 vs. 20 months, respectively). Our findings suggest that genetic factors predict the CNS progression of PVRL effectively, and the genetics-based CNS progression model might lead to stratification of treatment.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"3641-3649"},"PeriodicalIF":8.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141261501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.3324/haematol.2024.285676
Xavier Calvo
{"title":"Acute myeloid leukemia at first relapse: approaching the precipice.","authors":"Xavier Calvo","doi":"10.3324/haematol.2024.285676","DOIUrl":"10.3324/haematol.2024.285676","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"3463-3465"},"PeriodicalIF":8.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141497896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号